• Johnson & Johnson reported Phase 1 results showing its investigational oral drug JNJ-6143 shrank tumors in heavily pretreated advanced prostate cancer patients.
• Most treatment-related side effects were mild to moderate, supporting selection of a 50-mg once-daily dose for Phase 2 development.
• Results were presented at the European Society for Medical Oncology Congress 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610250330PR_NEWS_USPR_____NY80315) on October 25, 2026, and is solely responsible for the information contained therein.